
India-based Cipla gets new chief financial officer
pharmafile | June 8, 2016 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Cipla, Dr Reddy's, cfo, dr reddys
Cipla (NSE: CIPLA) has poached a top executive from Dr. Reddy’s by naming Kedar Upadhye as its new global chief financial officer.
The India-based pharma company had already appointed another senior Dr. Reddy’s executive, Umang Vohra, as its chief operating officer and this new move will see Upadhye leave his role as VP, global generics finance and head of investor relations to become CFO at Cipla.
The board at the company has approved the appointment and Upadhye will begin his role no later than August 16 2016.
India’s fifth largest drugmaker by sales posted disappointing results for Q4 of last year, with a 69% fall in profits from the same period the previous year. Among its many drugs are the anti-depressant, Escitalopram, HIV antiretroviral medicine, Limivudine, and corticosteroid, fluticasone propionate.
Related Content

Diagnosing the drug supply: Exposing the bad practice of manufacturers in the developing world
The world needs cheap generic drugs and Indian manufacturers offer a steady supply. However the …

Insys Therapeutics names current CFO Andrew Long as company’s new CEO
Insys Therapeutics has said Andrew Long will take over from Saeed Motahari as the company’s …

Dr Reddy’s demand more than $70 million from Indivior over generic Suboxone Film
Indian firm Dr Reddy’s is seeking at least $70 million from British firm Indivior Plc …






